Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jiedu Qingnao is a Traditional Chinese Medicine (TCM) formulation, typically administered as granules, developed by Beijing Anding Hospital of Capital Medical University. It is primarily used as an adjunctive therapy for the treatment of psychiatric disorders, specifically first-episode schizophrenia. The formula is designed based on TCM principles to clear heat, detoxify, and refresh the brain. Clinical studies evaluate its ability to enhance the efficacy of standard antipsychotic treatments while maintaining a favorable safety profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jiedu Qingnao.